Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2)
- Target
- VEGFR-2
- Molecular classification
- Receptor, Receptor Tyrosine Kinase, Transmembrane receptor
01
Overview
Vascular endothelial growth factor receptor 2 (VEGFR-2), also known as KDR (Kinase insert domain receptor) or Flk1 (Fetal liver kinase 1), is a type IV transmembrane receptor tyrosine kinase that serves as a principal high-affinity receptor for vascular endothelial growth factors, especially VEGF-A. It is essential for angiogenesis, vascular permeability, and cell survival/proliferation, making it a key target for anti-cancer therapies and other diseases characterized by abnormal vessel proliferation or function.
- Other names
- KDRFlk1CD309
02
Mechanism of action
Inhibition of KDR suppresses tumor growth by blocking neovascularization; neutralizing antibodies against KDR increase apoptosis within tumors.
03
Biological functions
AngiogenesisVascular permeabilityCell survivalCell proliferationSignal transduction
04
Disease associations
CancerAbnormal vessel proliferationAbnormal vessel function
05
Safety considerations
Potential for off-target effects on normal endothelial cellsDevelopmental toxicity due to role in angiogenesisResistance to therapy may develop
06
Interacting drugs
Monoclonal antibodies against KDR
1 more in the full profile.
07
Biomarkers
Q472H genetic variantSoluble VEGFR-2 levels in serumMicrovessel density
Beyond the preview
Go deeper on Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2).